Antengene Appoints Kevin Lynch as Chief Medical Officer

Mar 26, 2021View PDF

SHANGHAI, China and MELBOURNE Australia– March 25, 2021 – Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the appointment of Kevin Lynch, M.D. as Chief Medical Officer (CMO) of Antengene. In this position, Kevin will be responsible for the strategy, direction, and execution of the company’s clinical development plans and will directly report to Dr. Jay Mei, Founder, Chairman and CEO of Antengene.

Kevin Lynch



Kevin has almost 30 years of experience in R&D in the pharmaceutical industry. He has experience in multiple national, regional and global clinical roles, building organizations across Clinical Development and Medical Affairs previously at Novartis and Celgene. At Celgene, he was Vice President leading the European Clinical Development program before his most recent role in Asia-Pacific as Vice President and Head of Clinical Development and Medical Affairs.

Kevin has led all phases of clinical development across numerous novel therapies to commercial launch and post-registration development. Moreover, he has been closely involved in the clinical development of multiple transformational cancer therapies, including Glivec®, Tasigna®, Zometa®, Femara®, Revlimid®, Pomalyst®, and Vidaza®.

“The foundation of Antengene is a remarkable story and a great tribute to Dr. Jay Mei and his colleagues for their endeavor and vision,” said Kevin Lynch, “I am delighted to be able to work with Jay again, as well as a superb Antengene team, focused on diseases with clear unmet medical needs and a defined registration path. I am looking forward to exploring development opportunities in geographies where we have a presence, especially China, Australia and other Asian areas of R&D excellence and partnering with other pharma/biotech companies to build on each other’s strengths.”

“So glad to witness the senior management team of Antengene is becoming stronger than ever,” said Dr. Jay Mei, founder, chairman and CEO of Antengene. “Kevin has excellent professional skills and rich industry experience and I sincerely expect that he will make significant contributions to the clinical and corporate development of Antengene.”

Kevin has published and presented widely in many leading journals and conferences, including Annals of Internal Medicine, Nature Reviews Cancer, British Journal of Cancer, Clinical Cancer Research, Journal of Clinical Oncology and Blood, and has co-authored more than 100 journal articles and conference abstracts.

About Antengene
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets and obtained 12 investigational new drug approvals in Asia Pacific. The vision of Antengene is to “Treat Patients Beyond Borders”. Antengene aims to address significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics. Forward- looking Statement

The forward-looking statements

made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.